The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis.

Biosci Rep · 2025 · PMC12236107 · PMID 40459411

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP >0.05actually significant

in DSS-treated colons ( P =0.0092), whereas pharmacological inhibition of PAD4 with GSK484 significantly lowered NETs density in the same colon region ( P =0.0294, Figure 5b and c ). The administration of AZD3241 (alone) and AZD3241+GSK484 (combined) also lowered mucosal NETs formation, albeit this did not reach statistical significance ( P >0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.